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Abstracts / International Journal of Surgery 9 (2011) 363–369366UNOPERATED patients with unoperated infra-renal aortic aneurysms.
Adjustments between groups were made for age, sex, mean arterial
pressure, creatinine and the presence of diabetes using linear regression
analysis. PWV was represented as the mean [95% CI lower-upper].
Results: A total of 105 studies were performed, CONTROL n¼27,
THORACIC n¼30, ABDOMINAL n¼25, UNOPERATED n¼23. The ABDOM-
INAL group had an adjusted PWV of 11.9m/s [10.8-13.1], signiﬁcantly
higher than CONTROLS 8.8m/s [8.5-9.2] (p<0.001), THORACIC 8.8m/s [8.0-
9.6] (p<0.001), and UNOPERATED 8.9m/s [8.0-9.8] (p<0.001).
Conclusions: These data suggests that the replaced abdominal aorta
reduces arterial compliance. Thoracic grafting does not have an effect on
PWV indicating that the proximal aorta contributes less to tonometric
measurements of arterial stiffness. We provide a basis for future work to
investigate how prosthetic aortic replacement affects ventricular-arterial
coupling and the impact of pharmacological manipulation of vascular
function in such patients.PROGNOSTIC SIGNIFICANCE OF TOTAL DISEASE LENGTH IN
OESOPHAGEAL CANCER
J.D. Mason, L.l. Davies, T.D. Reid, M. Robinson, T.D. Crosby, S.A. Roberts,
W.G. Lewis. South East Wales Upper GI Cancer Network
Background: Oesophageal tumour length has long been considered an
important prognostic indicator in oesophageal cancer (OC), and typically
an operable tumour has been considered to be T1-3, N0-1, M0, with an
endoscopic deﬁned length of 5 cm or less.
Aims: The aim of this study was to test the hypothesis that endoluminal
ultrasound (EUS) deﬁned total length of disease (including both the
primary tumour and the position and number of proximal and distal
lymph nodes - ELoD) and the associated EUS lymph node metastasis count
(ELNMC) are better predictors of outcome than endoscopic OC length and
radiological TNM stage in patients undergoing potentially curative therapy
with either surgery or deﬁnitive chemoradiotherapy (dCRT).
Methods: 610 consecutive patients diagnosed with OC and managed by
a multidisciplinary teamwere staged by CT and EUS. The primary outcome
measure was survival from date of diagnosis.
Results: 302 patients received surgery and 308 patients received dCRT.
Univariable analysis revealed that survival was related to EUS T (p<0.001),
N (p<0.001), M1a (p¼0.041) stage, ELoD (p¼0.009), ELNMC (p<0.001),
and treatment type (p¼0.003). Multivariable analysis revealed two factors;
ELoD (HR 0.960 95% CI 0.923-0.999, p¼0.047) and ELNMC (HR 1.123, 95% CI
1.062-1.188, p<0.001) were independently associated with survival.
Conclusion: ELoD and ELNMC should become part of routine OC radio-
logical staging reports to optimise stage directed therapeutic outcomes.ROLE OF POSITRON EMISSION TOMOGRAPHY (PET) IN PANCREATIC
RESECTION FOR SUSPECTED PANCREATIC AND PERIAMPULLARY
CANCER
V. Allen, K.S. Gurusamy, A. Kalia, B.R. Davidson. Department of Surgery,
Royal Free Campus - UCL Medical School, 9th Floor Royal Free Hospital,
Pond Street, London. NW3 2QG
Background: A signiﬁcant proportion of patients undergo unnecessary
laparotomy because of incorrect diagnosis and understaging of pancreatic
and periampullary cancer.
Methods: A systematic review of studies assessing PET was performed.
Medline, Embase, Cochrane trials register, and Science Citation Index were
searched until November 2009. The gold standard test was laparotomy
with histological conﬁrmation. Meta-analysis was performed using
bivariate method and Littenberg-Moses method.
Results: Seven studies including 336 patients were included in the meta-
analysis for distinguishing benign from malignant disease. The summary
sensitivity and speciﬁcity were 0.892 and 0.745. This corresponds to a post-
test probability of 0.91 for a positive PET and 0.30 for a negative PET.
compared to a baseline probability of 0.75. Two studies including a total of
199 patients (who had undergone CT scan as standard work-up) were
included in the meta-analysis for assessing resectability with curativeintent. The summary sensitivity and speciﬁcity were 0.92 and 0.87. This
corresponds to a post-test probability of 0.56 for a positive PET (i.e. patient
has a 44% probability of curative resection if PET was positive) and 0.02 for
a negative PET (i.e. patient has a 98% probability of curative resection if PET
was negative) compared to a baseline probability of 0.15 (i.e. patient has
a 85%probability of curative resection if laparotomywas donewithout PET).
Conclusions: PET has no role in distinguishing benign and malignant
periampullary disease. A positive PET scan is unreliable but a negative PET
scan can conﬁrm curative resectability with high accuracy.AN ANALYSIS OF TUMOURIGENESIS IN HUMAN MESENCHYMAL STEM
CELLS EXPANDED IN VITRO
Clare Byrne. University of Aberdeen School of Medicine
5-10% of fractures demonstrate signiﬁcantly delayed healing or non-union.
Although skeletal ﬁxation has achieved limited success, no ideal treatment
for non-union exists1. One potential is the use of human mesenchymal
stem cells (hMSC's) to enhance fracture healing. While hMSC's display
immunosuppressive properties reducing the likelihood of rejection, side-
effects could include tumourigenesis2.
Objectives: 1. Do hMSC's become tumourigenic when expanded in
vitro and grown on agar?
2. Do time, cell concentration and passage number affect
tumourigenesis?
Materials & Methods: hMSC's were obtained from bone marrow aspi-
rates from iliac crests of patients undergoing surgical treatment for non-
union tibial fractures. Cells from 4 patients at 3 passages, positive (HCT
cells) and negative control lines (AA/CI cells), were seeded onto agar plates
at different concentrations. Plates were incubated at 37oC, 5% CO2 for 4
weeks. Tumour colony numbers (image 1) and tumourigenicity were
calculated weekly.
Image 1: Tumour colonyScale Bar: 20m ¼ 2cm
Results: 1. hMSC lines produced no colonies (p<0.001)
2. Higher cell concentrations result in increased colony numbers
(p<0.001)
3. Colony numbers decreased with time (p<0.001)
Conclusions: Tumourigenesis did not occur in hMSC's expanded in vitro.
These results may support existing studies conﬁrming hMSC's can be
safely expanded in vitro for therapeutic use.
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geneic animals. Blood 2003 Nov 15; 102(10):3837-44.CONTEMPORARY OUTCOMES OF URGENT CABG FOLLOWING NSTEMI;
URGENT CABG CONSISTENTLY OUT PERFORMS GRACE PREDICTED
SURVIVAL
J.D. Evans, S. Dudani, E. Senanayake, N.J. Howell, D. Pagano. University of
Birmingham, UK
Introduction: The GRACE registry has shown that in-hospital risk of
death following non-ST-segment elevationmyocardial infarction (NSTEMI)
is 5%, with a 11% mortality by 6 months. In GRACE, whilst 31% of patients
received PCI, only 7% received coronary artery bypass grafting (CABG). To
help identify patients at the highest risk following ACS the GRACE score
was developed. This identiﬁed a highest tertile of patients who had an in-
hospital death rate of 6.7% and a six-month death rate of 14%. The data on
the results of urgent CABG following NSTEMI are difﬁcult to interpret as
these often mix patients who have had STEMI and NSTEMI and include
urgent surgery for failed revascularisation.
Methods: 332 consecutive patients who had undergone CABG following
NSTEMI from 2005 to 2009 were identiﬁed. The GRACE score was retro-
spectively calculated from hospital notes at the time of admission, and late
survival data obtained from a prospectively maintained database.
Results: There were 6 deaths following surgery (1.8%). Survival at 6
months was signiﬁcantly higher than predicted by the GRACE score in all
groups. In patients with a predicted GRACE mortality of 0-10% the 6 month
mortality was 0.7%, with a predicted mortality of 10-20% the mortality was
2.6%, and in patients with a predicted mortality of >20% the mortality was
0. In patients with a EuroSCORE of <8, 5 year survival was 95%.
Conclusion: In hospital CABG performed 48 hours after NSTEMI is asso-
ciated with a low mortality risk and signiﬁcant improvements in the
GRACE predicted survival.‘THE IMPACT OF SIGN GUIDELINES ON CAROTID ENDARTERECTOMY IN
SOUTH-EAST SCOTLAND’
K.A. Gaba 1, Z. Raza 2. 1 University of Edinburgh; 2 Royal Inﬁrmary of
Edinburgh
Background: Several studies have demonstrated a beneﬁcial effect in
patients undergoing carotid endarterectomy (CEA) within two weeks of
suffering a focal neurological deﬁcit. However, there is a large variation
between units in the UK to provide CEA within the speciﬁed time.
Aim: This study aimed to evaluate whether the Edinburgh Vascular Unit
(EVU) has improved delays from neurological symptoms to surgery, in
accordance with Scottish Intercollegiate Guidelines Network (SIGN)
guidelines published in December 2008, which advocate the need for CEA
to be performed within two weeks of a neurological event.
Patients and Methods: Retrospective data related to CEA procedures
carried out at the EVU between March 2007 and June 2010 (n¼255) was
analysed. The medianwas calculated for days from neurological symptoms
to CEA, subdivided according to the four referring hospitals and whether
the data was pre- (n¼128) or post-publication of guidelines (n¼127).
Results: Median delay from symptoms to surgery decreased in all four
hospitals. Decrease in days from symptoms to surgery (p¼0.037) was
statistically signiﬁcant in one hospital. The percentage of patients under-
going CEA within two weeks after symptoms increased from 25% pre-
guidelines to 40.2% post-publication of guidelines. The percentage
undergoing CEA within four weeks after symptoms increased from 57% to
74.1% over the same period.
Conclusion: There has been a signiﬁcant improvement in CEA service
provision since the implementation of SIGN guidelines. Further resource
allocation is required to meet the two week target of CEA from symptoms
in all patients.DOES AN ENHANCED RECOVERY PROGRAMME AFFECT READMISSION
RATES FOLLOWING COLORECTAL RESECTION?
N.R. Hope BSc Med Sci 1, Ms. A.J. McKinley 2, Dr. L. Feldman 3. 1University
of Aberdeen; 2 Consultant colorectal surgeon, Aberdeen Royal Inﬁrmary;
3 Attending general surgeon, Montreal General Hospital
Background: Enhanced recovery after surgery (ERAS) is a clinical
pathway for surgical patients designed to reduce hospital stay.
Currently, this pathway is beginning to show that speciﬁc tailoring of
treatment before, during and after surgery can achieve this goal.
Patient safety following early discharge is of paramount importance.
This study aims to compare 30 day readmission rates of those patients
enrolled in an ERAS pathway versus those undergoing standard clinical
care.
Methods: Ethical approval was granted by the MUHC. The hospital data-
base and patient charts of 151 consecutive patients at Montreal General
Hospital who underwent colorectal resection between 1st June 2008 and
the 30th June 2009 were reviewed.
Results: 58 patients reviewed were in the ERAS pathway whilst 93
were reviewed in the standard care pathway. 30 day readmission rate
was 10.3% and 9.7% respectively (p¼0.98). Mean hospital stay was
7.21 (95% CI: 5.50, 8.92) days in the ERAS group and 10.55 (95% CI:
8.58, 12.52) days (p¼0.02). There were no statistically signiﬁcant
differences in patient ASA morbidity between the two groups
(p¼0.64).
Conclusions: These results support current literature that enrolment
in an ERAS pathway reduces hospital stay. Importantly, there is no
increased rate of readmission if discharged home earlier from
hospital. These data support the use of an ERAS pathway in routine
clinical use.AN AUDIT TO EVALUATE THE EFFECTIVENESS OF DERMATOSCOPY
Debbie Hunt 1, Mr. Christopher Duff 2, Mr. Stewart Watson 2. 1University
of Birmingham, UK; 2University Hospital South Manchester, UK
Background: Melanoma is an important cause of morbidity and
mortality. The incidence has risen to 1 in 87, and is increasing by 7% each
year.
Early recognition and excision remain the most successful method of
increasing patient survival. However, cure rates remain poor due to early
metastasis. The standard method of diagnosis is the naked eye with
accuracy ranging from 65-80%. There is therefore a need for an additional
diagnostic tool to ensure no malignant melanomas are missed and reduce
the number of unnecessary biopsies.
Purpose: This study looks at the efﬁcacy of the dermatoscope in
increasing the sensitivity and speciﬁcity of diagnosis for melanomas. The
sensitivity reﬂects the melanomas missed and the speciﬁcity reﬂects the
unnecessary biopsies.
Method: 89 pigmented lesions from patients presenting to clinic, within
an eleven-week period, were photographed with both a standard digital
camera and a dermatoscope-camera.
16 health care professionals – consultants and SpRs in plastic surgery,
general surgeons, and specialist nurses were asked, from each of the
photographs, which lesions were malignant.
Results: The overall sensitivity of the dermatoscope was 68%, compared
with 47% for the naked eye alone - an increase of 21%. This is statistically
signiﬁcant.
The overall speciﬁcity of the dermatoscope was 58% compared with 55%
for the naked eye - an increase of only 3%.
Conclusion: The dermatoscope is an effective tool in diagnosis. It signiﬁ-
cantly increases sensitivity of diagnosis, therefore reducing the number of
melanomas missed. The dermatoscope, however, did not signiﬁcantly
increase the speciﬁcity.
One argument is that the number of negative biopsies is acceptable in
order to catch as many melanomas as possible. In addition, the low
sensitivity would be reduced in practice when practitioners would be
more cautious with real patients, and have a lower threshold for
biopsy.
